Last updated: September 8, 2026
Desipramine hydrochloride is a mature, generic tricyclic antidepressant with no meaningful branded-market premium, no active composition-of-matter exclusivity, and limited public revenue disclosure. Its commercial value is concentrated in a small prescription market supported by low manufacturing costs, established clinical use, and limited but persistent demand. The principal business risks are supplier concentration, intermittent shortages, regulatory compliance costs, and substitution by newer antidepressants.
What is the current FDA status of desipramine hydrochloride?
Desipramine hydrochloride is an FDA-approved prescription antidepressant supplied primarily as immediate-release oral tablets. It is the hydrochloride salt of desipramine, a secondary-amine tricyclic antidepressant and active metabolite of imipramine.
| Regulatory attribute |
Status |
| Active ingredient |
Desipramine hydrochloride |
| Dosage form |
Immediate-release tablets |
| Primary indication |
Depression |
| FDA pathway |
Legacy NDA and abbreviated new drug applications |
| Controlled-substance status |
Not scheduled under the federal Controlled Substances Act |
| Reference brand |
Norpramin |
| Current commercial status |
Generic, multi-source, niche product |
| Biosimilar pathway |
Not applicable |
| Orange Book relevance |
Generic product listings and historical reference-drug information; no commercially meaningful active patent estate |
The original branded product, Norpramin, was developed and marketed decades ago. Current prescribing is largely supplied by generic manufacturers. FDA labeling identifies desipramine as a tricyclic antidepressant and includes class warnings concerning suicidality in pediatric and young adult patients, cardiovascular effects, seizure risk, anticholinergic effects, and overdose toxicity (U.S. Food and Drug Administration [FDA], n.d.-a).
Desipramine remains clinically relevant in selected patients but is not a first-line antidepressant for most new diagnoses. SSRIs, SNRIs, atypical antidepressants, psychotherapy, and other agents have displaced tricyclic antidepressants in routine treatment.
When did desipramine lose exclusivity?
Desipramine lost meaningful market exclusivity decades ago. Its commercial origin predates the modern Hatch-Waxman patent and generic framework, and the original product has long been exposed to generic competition.
The key commercial milestones are:
| Period |
Market event |
Commercial effect |
| 1960s |
Norpramin and desipramine introduced in the United States |
Originator-led market formation |
| 1980s-1990s |
Generic entry expanded |
Rapid price and share erosion |
| 2000s |
SSRIs and newer antidepressants dominated treatment initiation |
Desipramine became a specialty and legacy generic |
| 2010s |
Multi-source generic supply continued |
Low prices, limited manufacturer incentives |
| 2020s |
Niche demand remained; supply-chain risk increased |
Revenue stability depends more on availability than innovation |
No current commercial opportunity depends on patent term restoration, pediatric exclusivity, new chemical entity exclusivity, or an active branded patent cliff. The economically relevant question is whether a manufacturer can maintain supply at a margin that justifies manufacturing, quality, pharmacovigilance, and distribution costs.
What patents protect desipramine hydrochloride?
No material active patent protection is expected to block generic manufacture or sale of desipramine hydrochloride in the United States.
Composition-of-matter patents
The original desipramine molecule and hydrochloride salt are legacy technologies. Any original composition-of-matter rights expired many years ago. A new entrant would not face a live basic compound patent comparable to the estates surrounding recently approved small-molecule medicines.
Formulation patents
Desipramine is generally sold as an immediate-release tablet using conventional excipients and manufacturing processes. Publicly available product information does not indicate a commercially important extended-release, depot, transdermal, or other differentiated formulation protected by a current patent estate.
Potential formulation patents would have limited value unless they covered a product with meaningful FDA-recognized substitutability advantages. Conventional generic tablets are the dominant market form.
Method-of-use patents
There is no widely commercialized, currently protected method-of-use market for desipramine. Historical clinical research has examined desipramine for conditions beyond depression, including neuropathic pain, attention-deficit/hyperactivity disorder, panic disorder, and other psychiatric indications. Those uses do not create a current, high-value patent barrier.
Manufacturing and process patents
Process patents are unlikely to create a substantial entry barrier for a standard generic tablet. They could affect a particular supplier's route, impurity profile, or cost structure, but alternative routes and contract-manufacturing options generally reduce legal exclusivity risk. Manufacturing risk is more likely to arise from active pharmaceutical ingredient availability, validation, facility compliance, and economics than from enforceable blocking patents.
What is the Orange Book status of desipramine?
The Orange Book is relevant mainly as a record of FDA-approved reference and generic products, therapeutic equivalence information, and any listed patents or exclusivities. Desipramine's Orange Book position does not create a meaningful current barrier to generic competition.
A prospective applicant would normally evaluate:
- The reference listed drug and dosage strengths.
- Available abbreviated new drug applications.
- Therapeutic-equivalence codes.
- Any listed patents with unexpired terms.
- Any remaining exclusivity.
- The regulatory status of discontinued or withdrawn reference products.
For a mature generic such as desipramine, an ANDA applicant would ordinarily face bioequivalence, chemistry, manufacturing, and controls requirements rather than a patent-driven launch delay. FDA's Orange Book and Drugs@FDA databases are the controlling public sources for product and patent status (FDA, n.d.-b; FDA, n.d.-c).
How many patents cover desipramine hydrochloride?
There is no commercially significant active U.S. patent estate covering the basic desipramine hydrochloride tablet market. Historical patents may appear in patent databases, but their presence does not establish current enforceability.
| Patent category |
Current commercial importance |
| Original compound patent |
Expired |
| Hydrochloride salt patent |
Expired or historically irrelevant |
| Immediate-release tablet formulation |
No material blocking estate identified |
| Method-of-use patents |
No significant active market identified |
| Manufacturing-process patents |
Potentially supplier-specific, not generally blocking |
| Device or delivery-system patents |
Not relevant to the conventional product |
The absence of an active blocking patent does not eliminate litigation risk entirely. A manufacturer could face disputes involving data integrity, cGMP compliance, labeling, trade dress, supply contracts, or product liability. Those issues are separate from patent exclusivity.
Which companies are challenging desipramine exclusivity?
No prominent current Paragraph IV campaign is associated with desipramine hydrochloride. The product is already generic and does not present the economic profile that typically supports a high-value Paragraph IV challenge.
A Paragraph IV certification is most relevant when an ANDA applicant seeks to market a generic before listed patents expire. For desipramine, the absence of a commercially important unexpired patent estate means that entry would generally be based on ordinary ANDA approval and commercial readiness rather than a public patent challenge.
No material recent U.S. patent litigation or settlement agreement is associated with the conventional desipramine tablet market in the publicly visible regulatory record. Historical generic approvals may involve individual manufacturers, but those approvals are not evidence of an active exclusivity dispute.
What is the competitive landscape for desipramine?
Desipramine competes in two markets: the broader antidepressant market and the narrower tricyclic antidepressant market.
Direct and therapeutic competitors
| Competitor group |
Examples |
Competitive effect |
| Other tricyclics |
Nortriptyline, amitriptyline, imipramine, doxepin |
Similar legacy use; often broader clinical familiarity |
| SSRIs |
Sertraline, fluoxetine, citalopram, escitalopram |
First-line displacement in depression |
| SNRIs |
Venlafaxine, duloxetine, desvenlafaxine |
Competition in depression and pain-related treatment |
| Atypical antidepressants |
Bupropion, mirtazapine, trazodone, vortioxetine |
Differentiated tolerability or symptom profiles |
| Non-drug treatment |
Psychotherapy and behavioral treatment |
Reduces drug-only treatment demand in some patients |
Desipramine has pharmacologic properties that support continued niche use. It is relatively more noradrenergic than many other tricyclics and is less sedating than tertiary-amine tricyclics such as amitriptyline. Those attributes do not overcome the broader disadvantages of tricyclic therapy, including anticholinergic effects, orthostatic hypotension, cardiac conduction risk, drug interactions, and toxicity in overdose.
What formulations are protected by desipramine patents?
The commercial market is centered on immediate-release tablets. There is no major protected formulation franchise comparable to long-acting injectable, extended-release, abuse-deterrent, or modified-delivery products.
This limits product differentiation. Manufacturers generally compete on:
- Supply reliability.
- Wholesale acquisition cost.
- Contract pricing.
- Tablet-strength availability.
- Product quality and shortage avoidance.
- Distribution coverage.
- Ability to maintain multiple approved manufacturing sites.
The lack of formulation differentiation also means that a manufacturer cannot readily defend a premium through delivery technology. Any investment in a new formulation would require clinical, regulatory, and commercial justification in a market with low expected pricing.
What generic entry risks exist for desipramine?
Generic entry risk is structurally high because the product is already exposed to multiple-source competition and has no active patent moat. The risk is not a future patent cliff. It is persistent price competition and potential oversupply.
The main entry considerations are:
| Risk factor |
Assessment |
| Patent blockage |
Low |
| FDA approval complexity |
Moderate for a conventional tablet |
| Bioequivalence burden |
Standard oral-solid-dose requirements |
| Manufacturing complexity |
Low to moderate |
| API availability |
Potentially material |
| Pricing power |
Low |
| Substitution risk |
High from other antidepressants |
| Shortage opportunity |
Possible but episodic |
| Litigation probability |
Low relative to patented products |
| Long-term margin durability |
Weak |
A new entrant would need enough volume to cover regulatory maintenance, annual product testing, pharmacovigilance, distribution, and customer-service costs. The market may support additional supply during a shortage but may not support sustained high margins after competitors restore inventory.
How strong is the patent estate for desipramine?
The patent estate is weak for commercial purposes. Desipramine should be evaluated as a supply-and-compliance product rather than an intellectual-property product.
Patent-strength assessment
| Dimension |
Rating |
Reason |
| Compound exclusivity |
0/5 |
Historical rights expired |
| Formulation protection |
1/5 |
Conventional immediate-release tablet |
| Method-of-use protection |
1/5 |
No major active protected indication |
| Manufacturing protection |
1-2/5 |
Possible process know-how, limited blocking value |
| Regulatory exclusivity |
0/5 |
No current meaningful exclusivity |
| Brand differentiation |
1/5 |
Norpramin brand value is limited |
| Overall defensive strength |
1/5 |
Generic, mature, substitutable product |
The more relevant moat may be operational. A manufacturer with reliable API sourcing, a compliant facility, approved strengths, and established wholesaler relationships can retain share even without patents.
What is the financial trajectory for desipramine hydrochloride?
Public companies generally do not report desipramine revenue separately. It is usually grouped within broader generic portfolios, making precise product-level revenue, gross margin, and market-share figures unavailable from company filings.
The financial trajectory is nevertheless clear:
- Originator revenue was displaced by generic competition.
- Unit demand stabilized at a low level after clinical use shifted toward newer antidepressants.
- Price erosion reduced the value of each prescription.
- Revenue became dependent on continued availability and the number of active suppliers.
- Temporary shortages can increase volume or pricing, but those gains are difficult to sustain.
- Long-term growth is unlikely without a new indication, differentiated formulation, or supply disruption affecting competitors.
Revenue exposure
Desipramine is unlikely to represent a material share of revenue for a diversified generic manufacturer. Its financial importance is greater for a small portfolio company with a limited number of approved products.
For a potential acquirer or licensee, the asset may have value when:
- The buyer already has an approved oral-solid-dose platform.
- The product can be manufactured with low incremental cost.
- The seller has reliable API supply.
- The product fills a shortage-prone niche.
- The transaction includes multiple complementary generics.
- The product is sold through an established U.S. distribution network.
It is less attractive as a standalone investment when valuation depends on premium pricing, branded conversion, or patent-backed market protection.
What regulatory and manufacturing barriers affect the market?
The main barriers are operational rather than intellectual property-related.
Manufacturers must maintain FDA-compliant facilities, validated analytical methods, stability data, approved labeling, and controls for impurities and content uniformity. Tricyclic antidepressants also require careful packaging, labeling, and distribution because overdose can be medically serious.
API sourcing is a central risk. A limited number of qualified suppliers can create vulnerability to:
- Facility shutdowns.
- FDA warning letters or import alerts.
- Batch failures.
- Transportation disruptions.
- Changes in impurity specifications.
- Low-volume manufacturing decisions.
- Contract-manufacturer exits.
FDA's drug-shortage database is the relevant source for determining whether a shortage is active or resolved. Shortage conditions can improve near-term economics for remaining suppliers but can also trigger regulatory scrutiny and customer pressure to restore supply (FDA, n.d.-d).
What are the likely generic launch scenarios?
Base case
Existing generic suppliers continue serving a small, price-sensitive market. Revenue remains flat to declining in nominal terms, with periodic volume changes caused by prescribing patterns and supply availability.
Shortage-driven upside
One or more suppliers experience manufacturing or API problems. Remaining manufacturers gain temporary volume and may obtain better pricing. The benefit fades as supply returns.
Portfolio rationalization
Low prices and limited demand cause a manufacturer to discontinue one or more strengths or exit the product. This can increase concentration and create supply risk without creating durable pricing power.
Differentiated-product attempt
A company develops an extended-release or specialty-use formulation. This would require clinical and regulatory investment and would face uncertain adoption because physicians have many alternatives. The risk-adjusted commercial case is weak without a clearly superior clinical profile.
How does desipramine compare with other tricyclic antidepressants?
| Attribute |
Desipramine |
Nortriptyline |
Amitriptyline |
| Pharmacologic profile |
Relatively noradrenergic |
Noradrenergic with broader use |
More serotonergic and sedating |
| Sedation |
Lower relative to many TCAs |
Moderate |
Higher |
| Anticholinergic burden |
Material |
Material |
Often greater |
| Use in neuropathic pain |
Limited compared with amitriptyline |
Used in some cases |
Common legacy use |
| Generic availability |
Yes |
Yes |
Yes |
| Patent strength |
None of commercial significance |
None of commercial significance |
None of commercial significance |
| Market position |
Small niche |
Larger clinical familiarity |
Larger legacy and pain-related use |
| Commercial outlook |
Stable to declining |
Stable niche |
Stable but highly competitive |
Desipramine's lower sedation can support selection in specific patients, but it does not create a high-value commercial segment. Its principal advantage is clinical familiarity and availability, not exclusivity.
Key Takeaways
- Desipramine hydrochloride is a mature, multi-source generic antidepressant.
- Norpramin's original commercial exclusivity has long ended.
- No material active U.S. patent estate is expected to block conventional generic tablets.
- No meaningful current Paragraph IV campaign, patent litigation program, or settlement market is associated with the product.
- Immediate-release tablets dominate; differentiated formulations have no established commercial franchise.
- FDA and cGMP compliance, API sourcing, and supply reliability matter more than patent rights.
- Product-level revenue is generally not disclosed publicly.
- The financial trajectory is low-growth to declining, with temporary upside possible during shortages.
- The principal investment case is portfolio fit and supply execution, not patent-backed pricing power.
- Biosimilar risk is irrelevant because desipramine is a small-molecule drug, not a biologic.
FAQs about desipramine hydrochloride market and patents
Is desipramine hydrochloride still manufactured in the United States?
Generic desipramine hydrochloride remains commercially available through FDA-approved suppliers, but manufacturing may involve domestic and international facilities. Availability can vary by strength, distributor inventory, and supplier decisions.
Does desipramine hydrochloride have pediatric exclusivity?
There is no current commercial pediatric exclusivity period associated with the conventional desipramine tablet market. FDA labeling includes class-related pediatric and young-adult suicidality warnings.
Can a company obtain orphan-drug exclusivity for desipramine?
A new orphan designation would require a qualifying rare disease indication and supporting regulatory development. Existing use of desipramine does not itself create orphan exclusivity, and any new program would require a separate FDA review.
Is desipramine hydrochloride vulnerable to therapeutic substitution?
Yes. Prescribers can substitute other tricyclics, SSRIs, SNRIs, or atypical antidepressants depending on the clinical objective. Substitution is a major reason long-term pricing power is limited.
What would increase the value of a desipramine generic asset?
The strongest value drivers would be reliable supply, multiple approved strengths, low manufacturing cost, shortage exposure, dependable API sourcing, and inclusion in a broader generic portfolio. A standalone patent premium is not a realistic valuation basis.
References
-
U.S. Food and Drug Administration. (n.d.-a). Desipramine hydrochloride tablets prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-d). Drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
-
U.S. Food and Drug Administration. (2018). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
-
National Library of Medicine. (n.d.). Desipramine hydrochloride drug label information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
